Cargando…

Long-term use of proton-pump inhibitor on Alzheimer’s disease: a real-world distributed network analysis of six observational Korean databases using a Common Data Model

BACKGROUND: Dementia has a crucial impact on the quality of life of elderly patients and their caregivers. Proton-pump inhibitors (PPIs) are the most frequently prescribed treatment, but they have been shown to be associated with dementia. The data are inconsistent, however. OBJECTIVE: To investigat...

Descripción completa

Detalles Bibliográficos
Autores principales: Kim, Yerim, Seo, Seung In, Lee, Kyung Joo, Kim, Jinseob, Yoo, Jong Jin, Seo, Won-Woo, Lee, Hyung Seok, Shin, Woon Geon
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9647297/
https://www.ncbi.nlm.nih.gov/pubmed/36389281
http://dx.doi.org/10.1177/17562864221135700
_version_ 1784827357688758272
author Kim, Yerim
Seo, Seung In
Lee, Kyung Joo
Kim, Jinseob
Yoo, Jong Jin
Seo, Won-Woo
Lee, Hyung Seok
Shin, Woon Geon
author_facet Kim, Yerim
Seo, Seung In
Lee, Kyung Joo
Kim, Jinseob
Yoo, Jong Jin
Seo, Won-Woo
Lee, Hyung Seok
Shin, Woon Geon
author_sort Kim, Yerim
collection PubMed
description BACKGROUND: Dementia has a crucial impact on the quality of life of elderly patients and their caregivers. Proton-pump inhibitors (PPIs) are the most frequently prescribed treatment, but they have been shown to be associated with dementia. The data are inconsistent, however. OBJECTIVE: To investigate the association between PPIs use and Alzheimer’s disease (AD) or all-cause dementia in six observational Korean databases using a Common Data Model (CDM) and to perform a distributed network analysis. METHODS: Subjects aged over 18 years between 1 January 2004 and 31 December 2020. Among 7,293,565 subjects from 6 cohorts, 41,670 patients met the eligibility criteria. A total of 2206 patients who were included in both cohorts or with a history of dementia were excluded. After propensity matching, 5699 propensity-matched pairs between the PPIs and histamine-2 receptor antagonist (H(2)RA) users were included in this study. The primary outcome was the incidence of AD at least 365 days after drug exposure. The secondary outcome was the incidence of all-cause dementia at least 365 days after drug exposure. RESULTS: In the 1:1 propensity score matching, the risk of AD or all-cause dementia was not significantly different between the PPIs and H(2)RA groups in all six databases. In the distributed network analysis, the long-term PPI users (⩾365 days) were unassociated with AD [hazard ratio (HR) = 0.92, 95% confidence interval (CI) = 0.68–1.23; I(2) = 0%] and all-cause dementia (HR =1.04, 95% CI = 0.82–1.31; I(2) = 0%) compared with H(2)RA users. CONCLUSION: In the distributed network analysis of six Korean hospital databases using Observational Medical Outcomes Partnership (OMOP)-CDM data, the long-term use of PPI was not associated with a statistically significantly increased risk of AD or all-cause dementia. Therefore, we suggest that physicians should not avoid these medications because of concern about dementia risk.
format Online
Article
Text
id pubmed-9647297
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher SAGE Publications
record_format MEDLINE/PubMed
spelling pubmed-96472972022-11-15 Long-term use of proton-pump inhibitor on Alzheimer’s disease: a real-world distributed network analysis of six observational Korean databases using a Common Data Model Kim, Yerim Seo, Seung In Lee, Kyung Joo Kim, Jinseob Yoo, Jong Jin Seo, Won-Woo Lee, Hyung Seok Shin, Woon Geon Ther Adv Neurol Disord Original Research BACKGROUND: Dementia has a crucial impact on the quality of life of elderly patients and their caregivers. Proton-pump inhibitors (PPIs) are the most frequently prescribed treatment, but they have been shown to be associated with dementia. The data are inconsistent, however. OBJECTIVE: To investigate the association between PPIs use and Alzheimer’s disease (AD) or all-cause dementia in six observational Korean databases using a Common Data Model (CDM) and to perform a distributed network analysis. METHODS: Subjects aged over 18 years between 1 January 2004 and 31 December 2020. Among 7,293,565 subjects from 6 cohorts, 41,670 patients met the eligibility criteria. A total of 2206 patients who were included in both cohorts or with a history of dementia were excluded. After propensity matching, 5699 propensity-matched pairs between the PPIs and histamine-2 receptor antagonist (H(2)RA) users were included in this study. The primary outcome was the incidence of AD at least 365 days after drug exposure. The secondary outcome was the incidence of all-cause dementia at least 365 days after drug exposure. RESULTS: In the 1:1 propensity score matching, the risk of AD or all-cause dementia was not significantly different between the PPIs and H(2)RA groups in all six databases. In the distributed network analysis, the long-term PPI users (⩾365 days) were unassociated with AD [hazard ratio (HR) = 0.92, 95% confidence interval (CI) = 0.68–1.23; I(2) = 0%] and all-cause dementia (HR =1.04, 95% CI = 0.82–1.31; I(2) = 0%) compared with H(2)RA users. CONCLUSION: In the distributed network analysis of six Korean hospital databases using Observational Medical Outcomes Partnership (OMOP)-CDM data, the long-term use of PPI was not associated with a statistically significantly increased risk of AD or all-cause dementia. Therefore, we suggest that physicians should not avoid these medications because of concern about dementia risk. SAGE Publications 2022-11-08 /pmc/articles/PMC9647297/ /pubmed/36389281 http://dx.doi.org/10.1177/17562864221135700 Text en © The Author(s), 2022 https://creativecommons.org/licenses/by-nc/4.0/This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access page (https://us.sagepub.com/en-us/nam/open-access-at-sage).
spellingShingle Original Research
Kim, Yerim
Seo, Seung In
Lee, Kyung Joo
Kim, Jinseob
Yoo, Jong Jin
Seo, Won-Woo
Lee, Hyung Seok
Shin, Woon Geon
Long-term use of proton-pump inhibitor on Alzheimer’s disease: a real-world distributed network analysis of six observational Korean databases using a Common Data Model
title Long-term use of proton-pump inhibitor on Alzheimer’s disease: a real-world distributed network analysis of six observational Korean databases using a Common Data Model
title_full Long-term use of proton-pump inhibitor on Alzheimer’s disease: a real-world distributed network analysis of six observational Korean databases using a Common Data Model
title_fullStr Long-term use of proton-pump inhibitor on Alzheimer’s disease: a real-world distributed network analysis of six observational Korean databases using a Common Data Model
title_full_unstemmed Long-term use of proton-pump inhibitor on Alzheimer’s disease: a real-world distributed network analysis of six observational Korean databases using a Common Data Model
title_short Long-term use of proton-pump inhibitor on Alzheimer’s disease: a real-world distributed network analysis of six observational Korean databases using a Common Data Model
title_sort long-term use of proton-pump inhibitor on alzheimer’s disease: a real-world distributed network analysis of six observational korean databases using a common data model
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9647297/
https://www.ncbi.nlm.nih.gov/pubmed/36389281
http://dx.doi.org/10.1177/17562864221135700
work_keys_str_mv AT kimyerim longtermuseofprotonpumpinhibitoronalzheimersdiseasearealworlddistributednetworkanalysisofsixobservationalkoreandatabasesusingacommondatamodel
AT seoseungin longtermuseofprotonpumpinhibitoronalzheimersdiseasearealworlddistributednetworkanalysisofsixobservationalkoreandatabasesusingacommondatamodel
AT leekyungjoo longtermuseofprotonpumpinhibitoronalzheimersdiseasearealworlddistributednetworkanalysisofsixobservationalkoreandatabasesusingacommondatamodel
AT kimjinseob longtermuseofprotonpumpinhibitoronalzheimersdiseasearealworlddistributednetworkanalysisofsixobservationalkoreandatabasesusingacommondatamodel
AT yoojongjin longtermuseofprotonpumpinhibitoronalzheimersdiseasearealworlddistributednetworkanalysisofsixobservationalkoreandatabasesusingacommondatamodel
AT seowonwoo longtermuseofprotonpumpinhibitoronalzheimersdiseasearealworlddistributednetworkanalysisofsixobservationalkoreandatabasesusingacommondatamodel
AT leehyungseok longtermuseofprotonpumpinhibitoronalzheimersdiseasearealworlddistributednetworkanalysisofsixobservationalkoreandatabasesusingacommondatamodel
AT shinwoongeon longtermuseofprotonpumpinhibitoronalzheimersdiseasearealworlddistributednetworkanalysisofsixobservationalkoreandatabasesusingacommondatamodel